The federal agency introduced Elsa last month, boasting about the AI tool's ability to increase efficiency at the FDA.

The FDA is still on track to meet its user fee targets despite a higher-than-normal vacancy rate among scientific reviewers.

Dr. George Tidmarsh, a Stanford pediatrics adjunct professor and former pharmaceutical executive, is FDA Commissioner Marty ...

Two months after laying off 20% of its staff, Korro Bio says it has not retreated from its “3-2-1” corporate strategy as it prepares to release interim clinical data on its lead candidate KRRO-110 in ...

In 2024, HR leaders faced unprecedented pressure from senior executives concerned about continually rising healthcare costs.

Martin Muoto’s real estate funds at Sola Impact were examined by the regulator over intercompany deals and allegations of ...

Dr. Peter Marks, the former director of the FDA’s Center for Biologics Evaluation and Research, urged public health leaders ...

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

Decriminalization was a three-year pilot project introduced by the BC NDP to help people access harm reduction services and ...

MTX-001 recognized for its clinical and commercial potential for treating chronic non-healing venous leg ulcers (VLUs)RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) -- Merakris ...

Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, the Duchenne patient community fears losing access to Elevidys while the ...

The American Benefits Council is urging Congress to consider the cost to employers, workers and their families as it proposes ...